Cardinal Health Inc. (CAH)
Compared to Estimates, Cardinal (CAH) Q4 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Cardinal (CAH) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Cardinal Health (CAH) Tops Q4 Earnings Estimates
Cardinal Health (CAH) came out with quarterly earnings of $2.08 per share, beating the Zacks Consensus Estimate of $2.03 per share. This compares to earnings of $1.84 per share a year ago.
Cardinal Health to Extend Reach by Acquiring Solaris Health
Cardinal Health's multi-specialty management services organization (MSO), The Specialty Alliance, plans to acquire urology MSO Solaris Health. Cardinal Health will enable the acquisition by providing about $1.9 billion in cash to The Specialty Alliance and will own about 75% of The Specialty Alliance after the acquisition of Solaris Health, Cardinal Health said in a Tuesday (Aug.
CAH Q4 Earnings Beat Estimates, '26 EPS View Up, Stock Falls
Cardinal Health's fourth-quarter fiscal 2025 results benefit from solid Medical and Other segments' revenue growth. However, OptumRx contract expiry hurts Pharmaceutical segment sales.
Cardinal Health, Inc. (CAH) Q4 2025 Earnings Call Transcript
Cardinal Health, Inc. (NYSE:CAH ) Q4 2025 Earnings Conference Call August 12, 2025 8:30 AM ET Company Participants Aaron E. Alt - Chief Financial Officer Jason M.
Cardinal Health Stock Tumbles on Earnings and $1.9 Billion Solaris Health Purchase
The company will acquire Solaris Health, a urology management services organization, for around $1.9 billion in cash.
Cardinal Health Q4 Preview: Accelerating Autoimmune, Urology And Oncology, Buy
Initiating Cardinal Health, Inc. with a Buy rating and $239 fair value, driven by specialty distribution growth and successful GMPD turnaround. Specialty segments in autoimmune, urology, and oncology are strategic growth drivers, outpacing traditional pharmaceutical markets and accelerating overall company growth. Recent urology acquisitions and strong specialty focus position Cardinal for above-market growth, despite near-term revenue headwinds from a customer contract expiration.
4 Dental Supplies Stocks Likely to Gain Amid Rising Tariff Risks
Here, we discuss four stocks from the Dental Supplies industry that are likely to generate wealth for investors amid tariff uncertainty. These are MCK, CAH, WST and COO.
Can Sustained Product Demand Drive CAH Stock Before Q4 Earnings?
The continued solid uptake of Cardinal Health's products is expected to have driven fiscal fourth-quarter revenues despite an uncertain macroeconomic environment.
What Analyst Projections for Key Metrics Reveal About Cardinal (CAH) Q4 Earnings
Beyond analysts' top-and-bottom-line estimates for Cardinal (CAH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.
Should Value Investors Buy Cardinal Health (CAH) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
